Trials / Terminated
TerminatedNCT01069120
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Repros Therapeutics Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Safety and efficacy study of 25 and 50 mg doses of Proellex
Detailed description
The study is intended to provide more abundant safety and efficacy data of both the 25 and 50 mg doses of Proellex than ZPU-301, ZPU-302, ZPU-303 and ZPU-304 alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Proellex | 2, 25 mg capsules once per day |
| DRUG | Proellex | 1, 25 mg capsule once per day |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2010-02-17
- Last updated
- 2014-08-21
- Results posted
- 2014-08-21
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01069120. Inclusion in this directory is not an endorsement.